Beruflich Dokumente
Kultur Dokumente
AND THE
FUTURE
Copyright 2010 - International Vaccine Institute. All rights reserved International Vaccine Institute Seoul National University Research Park San 4-8 Nakseongdae-dong, Gwanak-gu, Seoul, Korea 151-919 Tel : +82-2-872-2801 Fax : + 82-2-872-2803 Contact : iviinfo@ivi.int
www.ivi.int
www.ivi.int
FUTURE
IVIs Vision: The effective control of poverty-related infectious diseases in developing countries through the accelerated and sustainable introduction of new-generation vaccines. IVIs Mission: To combat infectious diseases through innovations in vaccine design, development, and introduction, addressing the needs of people in developing countries.
CONTENTS
04. LETTER FROM THE DIRECTOR GENERAL 05. WHO WE ARE
IVIs Bench to Field Approach Historical Milestones
14. DONORS 15. PARTNERS 17. BOARD OF TRUSTEES 18. SCIENTIFIC ADVISORY GROUP 19. SIGNATORY COUNTRIES
Dear Friends, We live in an era of unprecedented gaps in health between rich countries and poor countries. Sometimes called the 90/10 gap, developing countries experience 90% of the worlds infectious disease mortality, yet only 10% of resources devoted to the control of infectious diseases find their way to the developing world. The good news is that vaccines have repeatedly been demonstrated to be the most cost-effective tools for preventing infectious diseases and recent advances in biotechnology offer the prospect of new vaccines against diseases for which no previous vaccines existed and of vastly improved versions of existing vaccines. As well, there are now unprecedented resources being made available from public sector entities such as the Bill & Melinda Gates Foundation, the Wellcome Trust, the GAVI Alliance, and OECD governments to develop and deploy new vaccines for the worlds poorest people. The International Vaccine Institute (IVI), located in Seoul, Republic of Korea, was established to assist efforts to close the gap in vaccines for the developing world versus those for the industrialized world by conducting research and delivering technical assistance. The IVI is the worlds only international research organization devoted solely to bringing new vaccines to the poor populations of the developing world. To date, 40 countries and the WHO have signed the IVI Establishment Agreement. During the years since the IVI was established in 1997, the Institute has become an important partner in global efforts to develop and deploy new vaccines for the poor. It has conducted major programs of field research on new vaccines against enteric infections, pneumonia, meningitis, dengue fever, and Japanese encephalitis in 29 countries of Asia, Africa, and Latin America. It has also provided technical assistance in vaccine production, regulation, and evaluation to professionals in more than 20 countries in Asia, Africa, and Latin America. The IVIs growth has been made possible by generous support from an increasing number of donors. In this respect, the Republic of Korea has played a pivotal role, providing a portion of the IVIs operating budget, as well as a headquarters building with state-of-the-art laboratories. On behalf of the IVI and the broader international community, I would like to extend profound gratitude to the government of Korea for its continuous support and generosity since the inception of the IVI. The wonderful support of the government of Korea to the IVI is no better typified than by the generosity of Koreas First Lady, Madam Kim Yoon-ok, in serving as the Honorary President of the Korea Support Committee for the IVI. With the completion of the beautiful IVI headquarters building in 2003, the Institute has launched an exciting laboratory sciences program. The laboratory program has already made significant scientific advances, including the development of novel adjuvants that have the potential to significantly increase the effectiveness of oral vaccines; the discovery of a new common protein antigen that could serve as a simple and inexpensive vaccine against shigellosis, a disease that kills 1 million children annually; the development of new animal models for Shigella to evaluate future shigellosis vaccines; discovery of an entirely new way of administering vaccines without injections sublingually; and the completed development of three new vaccines, one against cholera and two against typhoid fever, which have been transferred to producers in developing countries. The recent completion of a new Biosafety Level 3+ laboratory in our headquarters will also allow the IVI to develop vaccines against dangerous pathogens, including avian influenza (H5N1). In closing, I would like to acknowledge the importance to our programs of the collaboration of many institutions and individuals, from both the private and public sectors and from both the industrialized and developing worlds. And I would like to thank especially the scientists, public health officials, and other collaborators in developing countries who have allowed us to join with them in their work to reduce morbidity and mortality in their countries. It has been an honor to have shared the hopes and aspirations of these dedicated persons.
WHO WE ARE
IVIs Current Disease Priorities
Diarrheal and enteric diseases:
Cholera Typhoid/paratyphoid fever Shigellosis (bacterial dysentery) Rotavirus Respiratory infections and meningitis: Haemophilus influenzae type b (Hib) Pneumococcal disease Influenza (seasonal and pandemic) Tuberculosis
World economic prosperity is dependent upon global development, particularly in the worlds leastdeveloped countries. This can only be accomplished by ensuring the health of children. In 2008 it was estimated that 8.8 million children who were under five years old died. Of these child deaths, 98% occurred in developing countries and the majority was caused by infectious diseases. The International Vaccine Institute (IVI) is an international organization exclusively devoted to developing and introducing vaccines for people, especially children, in the worlds poorest countries. Created by the United Nations Development Programme, the IVI began formal operations as an independent international organization in 1997. Hosted by the Republic of Korea, the IVI has 40 countries and the World Health Organization as signatories to its charter to date. The IVIs comprehensive research programs address vaccines against neglected diseases that mainly affect developing countries such as enteric infections, bacterial causes of pneumonia and meningitis, dengue, influenza, tuberculosis, and Japanese encephalitis. Complementing its research, the IVI is actively engaged in training and technical assistance to enhance the capacity of developing countries in the vaccine sciences. This work is made possible through the governance and guidance of the Institutes Board of Trustees and Scientific Advisory Group, dedication and skill of the Institutes staff and collaborators, and support from international organizations, national governments, foundations, companies, and private individuals. The Republic of Korea, in particular, contributes to the Institutes operating budget and provided its state-of-the-art headquarters building on the campus of Seoul National University.
04 / 05
WHERE WE WORK
MONGOLIA DEMOCRATIC PEOPLES REPUBLIC OF KOREA CHINA BANGLADESH LAOS INDIA MYANMAR THAILAND NIGER GHANA TANZANIA MOZAMBIQUE ETHIOPIA SRI LANKA INDONESIA VIETNAM CAMBODIA MALAYSIA PHILIPPINES PANAMA COLOMBIA TAIWAN GUATEMALA EL SALVADOR NICARAGUA VENEZUELA REPUBLIC OF KOREA
PAKISTAN EGYPT
BRAZIL
Sincerely,
The IVIs goal is accelerated development and deployment of new vaccines for the poor in
IVIs in-house capabilities and activities along the bench to field continuum
Laboratory process development Assays development (immuno-monitoring) Technology transfer for large-scale production Clinical trials
developing countries. To accomplish its goal, the Institute uses an innovative bench to field strategy in which it conducts and coordinates activities all along the full continuum of vaccine discovery, vaccine development, and vaccine deployment. This is greatly facilitated by the Institutes in-house scientific and technical capacity in disciplines all along the continuum, as well as the Institutes multi-disease focus. This broad range of skill and capacity allows the IVI to:
Develop a new or improved vaccine; Develop immunological assays and molecular analyses for use in the field; Conduct clinical trials of experimental vaccines; Conduct vaccine process and scale-up research; Transfer the technology for vaccine production to high-quality manufacturers; and Conduct demonstration projects of existing vaccines, epidemiological studies, economic and policy analyses, and socio-behavioral studies to provide the evidence needed to make vaccine introduction rational and economically sustainable, and to make the case for its use to global and national level policymakers, donor agencies, and the international health community.
Genotyping of pathogens Novel antigens Novel adjuvants New delivery mechanisms New routes of administration
VACCINE DEVELOPMENT
Collection of epidemiological, economic & socio-behavioral data Studies of vaccine feasibility, acceptance & field effectiveness Data synthesis (cost-effectiveness and impact analyses) and dissemination
06 / 07
2010
HISTORICAL MILESTONES
APR 2010
1990
Dr. John D, Clemens, Director General of the IVI, receives the Albert B. Sabin Gold Medal from the Sabin Vaccine Institute in recognition of his contributions to public health in the developing world and efforts in vaccine diplomacy. Launch of the shigellosis vaccine development program (Pan-Shigella Surface Protein 1 Sublingual Vaccine Against Dysentery Program) with a $2.5 million grant from PATH. Launch of the Typhoid Fever Surveillance in sub-Saharan Africa Program (TSAP) with a $7 million grant from the Bill & Melinda Gates Foundation. Launch of additional field studies of IVIs oral killed whole cell cholera vaccine to determine optimal use of the vaccine with a $7.5 million grant from the Bill & Melinda Gates Foundation. Licensure of IVIs oral killed whole cell cholera vaccine in India, making it the first vaccine developed under support by the Bill & Melinda Gates Foundation to achieve licensure. Designer: Include Shanchol vial pic Inauguration of state-of-the-art immune-monitoring laboratory in Kolkata, India, jointly run by IVI and the National Institute of Cholera and Enteric Diseases (NICED).
JAN 2009
Launch of the Policy and Economic Research Unit with support from the Swedish International Development Cooperation Agency (Sida). Madam Kim Yoon-ok, First Lady of Korea, becomes the third Honorary President of the Korea Support Committee for the IVI. Completion of BSL3+ laboratory. Launch of the Vi-based Vaccines for Asia (VIVA) Initiative with an $11.9 million grant from the Bill & Melinda Gates Foundation. Commemoration of the 10th Anniversary. Launch of project to introduce vaccines for children in the Democratic Peoples Republic of Korea (DPRK). Launch of the Cholera Vaccine Initiative (CHOVI) with a $22 million grant from the Bill & Melinda Gates Foundation. IVI Board of Trustees elects Prof. Ragnar Norrby as its new Chairman. Eighth Anniversary ceremony held in the presence of Koreas First Lady Madam Kwon Yang-suk. IVI headquarters building is inaugurated by President Roh Moohyun of the Republic of Korea.
SEPT 2004
Madam Kwon Yang-suk, First Lady of Korea, becomes the second Honorary President of the Korea Support Committee for IVI. Pediatric Dengue Vaccine Initiative (PDVI) receives a $55 million grant from the Bill & Melinda Gates Foundation. Opening of the new headquarters building, generously donated by the government of Korea, and initiation of IVIs new Laboratory Sciences Division. The Board of Trustees meets with Mr. Kim Dae-jung, President of the Republic of Korea, at the presidential office of Cheong Wa Dae. Launch of the Diseases of the Most Impoverished (DOMI) Program, with a $40 million grant from the Bill & Melinda Gates Foundation. Madam Lee Hee-ho, First Lady of Korea, becomes the first Honorary President of the Korea Support Committee for the IVI. The Board of Trustees appoints Dr. John D. Clemens as the first Director General of IVI. Inaugural meetings of the governing Board of Trustees and the Institute Support Council convene in Seoul, with Prof. Barry Bloom as the Boards first Chairman.
MAY 1997
IVIs Establishment Agreement goes into effect after receiving three ratifications at the United Nations Headquarters in New York. The government of the Republic of Korea (Ministry of Education and Human Resources Development) sets up a special task force at Seoul National University for the establishment of the IVI (chaired by Prof. Park Sang-dai). UNDP opens an interim office of the IVI on the campus of Seoul National University in Seoul, Republic of Korea. The Site Selection Committee, meeting at UNDP, recommends that the IVI be located in Seoul, Republic of Korea, and that the Institute carry out its activities through close partnerships with centers of excellence in other countries in the region. Six Asian countries submit proposals to UNDP to host the IVI. Based on a feasibility study, a formal proposal to establish the IVI as an outgrowth of the CVI in a developing country in Asia is adopted by UNDP. The World Summit on Children at the United Nations adopts a declaration calling for concerted international action to promote childrens health in developing countries, leading to the creation of the Childrens Vaccine Initiative (CVI).
OCT 2008
JUL 2003
DEC 1995
JUN 2003
NOV 2009
OCT 2007
JAN 1995
MAR 2002
JUN 1994
OCT 2009
MAY 2007
JAN 2000
FEB 2009
OCT 2006
APR 1999
MAR 1994
APR 2006
APR 1999
SEPT 1993
OCT 2005
OCT 1997
SEPT 1990
OCT 2004
IVIS ACHIEVEMENTS
WHAT WE DO
In order to achieve rational adoption of new vaccines by developing countries in a timely and appropriate manner, the IVI has deployed a strategy that involves a full range of activities from the upstream (vaccine discovery and development) to the downstream (translational field research to generate evidence for policy) to make this happen. The IVIs in-house capacity in these areas is made possible through its programs in Translational Research and Laboratory Sciences, and state-ofthe-art laboratories including a Bio Safety Level 3+ (BSL3+) high-containment facility. A tight programmatic linkage exists between Laboratory Sciences and Translational Research, and is an integral part of IVIs success.
Translational Research
IVIs Translational Research programs conduct the diverse types of research needed to provide the evidence required by policymakers to introduce new vaccines into public health programs in developing countries. These studies include assessments of the disease burden and risk factors for specific diseases in different populations; clinical trials and demonstration projects of vaccines; economic analyses of the cost-effectiveness of introducing new vaccines; assessments of the public demand and willingness to pay for new vaccines; and policy assessments of the feasibility and financial sustainability of introducing new vaccines. The multi-disciplinary group of scientists in this division includes experts in epidemiology, clinical trials, computer science, biostatistics, economics, behavioral sciences, and policy analysis.
OUR PARTNERS
The IVIs global network of partnerships extends from the WHO to leading research centers and biotechnology and vaccine production companies both in industrialized and developing countries; national governments; and public and private health facilities.
08 / 09
which typhoid fever is a public health problem, and it recently launched the Typhoid Fever Surveillance in sub-Saharan Africa Program (TSAP), with funding from the Bill & Melinda Gates Foundation, to conduct sentinel site surveillance of typhoid fever in up to 15 African countries.
LABORATORY SCIENCES
The Laboratory Sciences programs have more than 50 scientific staff and over 10 senior scientists trained in areas spanning from molecular biology to microbiology, bioinformatics, mucosal immunology, clinical immunology, and vaccine production. Equipped with stateof-the-art equipment, the IVIs laboratories also include a combined (animal/clinical) high security (BSL3+) laboratory for conducting studies on dangerous pathogens. The Laboratory Sciences programs conduct quality-controlled assays and procedures for typing microbes from field isolates and conduct technology transfer activities to affiliated laboratories in developing countries. Extensive efforts are being devoted to designing novel cost-effective vaccine formulations amenable to large-scale production, as well as novel adjuvant molecules for enhancing vaccine potency.
Support from the Bill & Melinda Gates Foundation, the Ministry of Education, Science and Technology of the Republic of Korea, LG Corporation, Swedish International Development Cooperation Agency (Sida), and UBS Optimus Foundation.
The goal of Vaccine Product Development and Technology Transfer is to develop new or improve existing vaccines and vaccine manufacturing technology, and to make them available to qualified producers in developing countries. The program works to maximize the yield of vaccine antigens and to optimize the purification of these antigens to help keep manufacturing costs low, thereby making vaccines more affordable for use in developing countries. The program also develops quality control assays for vaccines to ensure that the final product meets quality standards. Finally, the program works with developing country producers and national regulatory authorities to ensure a smooth technology transfer process, and conducts capacity-building and training activities as well.
US CDC
10 / 11
Specific vaccines the Vaccine Product Development and Technology Transfer Department is working on
Modified killed whole cell oral cholera vaccine - The IVI modified a vaccine that was produced and used only in Vietnam so that it complies with WHO guidelines for quality production standards. The new vaccine formulation was found in Phase II clinical trials in Vietnam and India to be safe and to elicit a stronger immune response in adults and children than the previous vaccine. A vaccine producer in India was selected to be the first producer for the technology transfer of this vaccine, which is now licensed in India under the trade name ShancholTM and is being evaluated in a Phase III clinical trial in Kolkata, India. This work is being conducted under the Cholera Vaccine Initiative (CHOVI). Vi-DT conjugate typhoid fever vaccine - In collaboration with the US National Institutes of Health, the IVI developed a Vi conjugate vaccine using diphtheria toxoid (DT) as the carrier protein. This work, including the technology transfer of the vaccine to a producer in India and clinical testing in India, is being conducted through the Vi-based Vaccines for Asia (VIVA) Initiative. High-yield Vi capsular polysaccharide vaccine against typhoid fever - The IVI optimized the production, yield, purification, and testing of this vaccine. These improvements have resulted in a purer, more uniform product that produces three times the amount of Vi over standard batch culture methods. These improved technologies, which will help to keep manufacturing costs to a minimum while also meeting GMP requirements, were transferred to selected developing country vaccine producers. Paratyphoid A-diphtheria toxoid conjugate vaccine - In response to the emergence of paratyphoid A fever in China and other Asian countries, the IVI is developing a conjugate vaccine using diphtheria toxoid (DT) as the carrier protein. The eventual goal is to develop a bivalent Vi-DT and paratyphoid A-DT conjugate vaccine against enteric fever that will be available for technology transfer to developing country manufacturers.
Respiratory Pathogens Vaccine Program INVESTING IN VACCINES CHILDREN AND THE FUTURE
Support from the Korea International Cooperation Agency (KOICA), Pfizer, sanofi pasteur, Sida, the World Health Organization, and the US Centers for Disease Control and Prevention. This program generates evidence of the disease and economic burden of bacterial meningitis and pneumonia-caused by Hib, meningococcal disease, and pneumococcal disease (Streptococcus pneumoniae )-and of influenza to inform policy decisions regarding the use of vaccines against these pathogens. It also assists public health programs in implementing vaccination programs to combat these diseases.
Department of Immunology
Support from the Bill & Melinda Gates Foundation, Sida, Korea Foundation for International Scientific Cooperation and Technology (KICOS), Korean Ministry of Health and Welfare, National Research Foundation of Korea, Korean Ministry of Education, Science and Technology, Korea Research Institute of Bioscience and Biotechnology, Arizona State University, Japan Society for the Promotion of Science, and Indian Council of Medical Research.
Support from the Government of the Republic of Korea, AusAID, Bill & Melinda Gates Foundation, GlaxoSmithKline Biologicals, Rockefeller Foundation, Sartorius AG, Government of Kuwait, Swedish International Development Cooperation Agency (Sida), Merck Vaccines, and Korea Exchange Bank (KEB) Foundation.
A feature frequently overlooked in vaccine efforts for the developing world is the importance of training and capacity-building. The IVI recognizes the significance of training and capacity-building for its developing country partners, which is crucial for enhancing the sustainability of vaccination programs. Thus a key element of IVIs strategy to accelerating the deployment of vaccines in developing countries is a strong focus on training and technical assistance. IVIs training and technical assistance activities range from formal didactic workshops to informal hands-on training. The IVI provides training on modern methods and standards for vaccine production and evaluation, as well as on research methods needed to generate evidence to inform vaccine policy. The Institute also provides technical assistance to vaccine producers in developing countries for the production of new vaccines and participates as a trainer in the Global Training Network of the World Health Organization. The aim of all of these activities is to increase the capacity of developing country professionals in the vaccine sciences.
Department of Microbiology
US CDC
Support from the Bill & Melinda Gates Foundation, Korea Foundation for International Scientific Cooperation and Technology (KICOS), Korea International Cooperation Agency (KOICA), Korean Ministry of Education, Science and Technology, Korean Ministry of Health and Welfare, Korea Research Council of Fundamental Science and Technology, Korea Research Institute of Bioscience and Biotechnology, National Research Foundation of Korea, Swedish International Development Cooperation Agency (Sida), PATH, and Woongji Corporation.
12 / 13
Key activities:
The Annual International Advanced Course on Vaccinology in the Asia-Pacific Region, a six-day vaccinology course held at the IVI headquarters in Seoul, which provides an overview of the vaccine sciences from the principles of vaccine design to policy issues. Running for 10 years, the course has successfully trained countless scientists, public health officials, and decision makers from developing countries in Asia, Africa, and Latin America. Major international symposia hosted by the IVI have included the first symposium on human papillomavirus vaccination in the Asia-Pacific and Middle East regions, pneumococcal vaccination in the Asia-Pacific region, and hepatitis E. Training on Good Clinical Laboratory Practices (GCLP) at the IVI/National Institute of Cholera and Enteric Diseases (NICED) immune-monitoring laboratory in Kolkata, India in collaboration with WHO Special Program for Research and Training in Tropical Diseases (TDR). Training of North Korean scientists in laboratory-based methods for diagnosis of Hib and Japanese encephalitis and in epidemiology, surveillance and vaccine evaluation. Training on Good Manufacturing Practices (GMP) in vaccine production (China, Vietnam). Training on production and lot release testing of killed, oral cholera and Vi polysaccharide vaccines (China, Vietnam, India, Indonesia, Pakistan). Training on Good Clinical Practice (GCP) standards and methods for trials of vaccines in humans (Bangladesh, Cambodia, China, India, Indonesia, Pakistan, Philippines, Thailand, Vietnam). Post-doctoral training in vaccine sciences (France, Republic of Korea, Sweden, United States, Japan, Vietnam, Mongolia). Workshops on data management methods, microbiological techniques, and social science methods for field studies of vaccines (Bangladesh, China, India, Indonesia, Mozambique, Pakistan, Thailand, Vietnam). The Scholars in Residence Program, in which world-renowned scientists are invited to the IVI on a regular basis to give lectures and to share their expertise with IVI scientists and the Korean scientific community. Clinical trials training course for the Developing Country Vaccine Manufacturers Network (DCVMN) (Brazil, China, India, Indonesia, Republic of Korea, South Africa, Vietnam).
DONORS
Core funding to the IVI is provided by the governments of the Republic of Korea, Kuwait, and Sweden. In addition, publicand private-sector donors provide support for the Institutes research and programs. Countless individuals also provide support to the IVI. While there are too many individuals to list, their generosity is deeply appreciated.
MAJOR DONORS Government & foundations & non-profit organizations :
Arizona State University, USA AusAID Bill & Melinda Gates Foundation European Union Government of Kuwait The GAVI Alliance Indian Council of Medical Research, India Japan International Cooperation Agency (JICA) Japan Society for the Promotion of Science, Japan Johns Hopkins University (PneumoADIP) Korean Government & organizations - Community Chest of Korea - Korea Bio-MAX Institute, Seoul National University - Korea Centers for Disease Control and Prevention - Korea Exchange Bank (KEB) Foundation - Korea Health Industry Development Institute - Korea Institute of Tuberculosis - Korea International Cooperation Agency (KOICA) - Korea Research Council of Fundamental Science and Technology (KRCF) - Korea Research Foundation - Korea Research Institute of Bioscience and Biotechnology - Korea Rural Development Administration - Korea Science and Engineering Foundation (KOSEF) - Ministry of Education, Science and Technology - Ministry of Health and Welfare - Ministry of Unification - Seoul National University - Yanghyun Foundation Nagasaki University, Japan Netherlands Vaccine Institute, The Netherlands
PATH (Program for Appropriate Technology in Health) PneumoADIP/Johns Hopkins University, USA Portland State University, USA Program for Appropriate Technology in Health (PATH), USA Rockefeller Foundation, USA Swedish International Development Cooperation Agency (Sida), Sweden U.S. Agency for International Development (USAID) U.S. National Institutes of Health (USNIH) U.S. National Science Foundation (NSF) UBS Optimus Foundation, Switzerland United Nations (UNDESA) United Nations Development Program (UNDP) University of North Carolina at Chapel Hill, USA US CDC Foundation, USA US Centers for Disease Control and Prevention (CDC), USA VIDO, University of Saskatchewan, Canada Wellcome Trust World Health Organization (WHO)
PARTNERS
Cuba : Instituto of Tropical Medicine Pedro Kouri Democratic Peoples Republic of Korea : Academy of Medical Sciences; Ministry of Public Health France : Agence de Mdecine Prventive (AMP); Centre National de la Recherche Scientifique (CNRS); Epicentre; LInstitut National de la Rcherche Agronomique (INRA); Institut National de la Sant et de Recherche Mdicale (INSERM); Institut Pasteur; sanofi pasteur Germany : Bernhard-Nocht Institute for Tropical Medicine; Sartorius AG Ghana : Agogo Presbytarian Hospital; Kumasi Centre for Collaborative Research in Tropical Medicine; School of Medical Sciences, Kwame Nkrumah University of Science & Technology (KNUST) Hong Kong : Chinese University of Hong Kong India : Amrita Institute of Medical Sciences; All India Institute of Medical Sciences (AIIMS); Bharat Biotech; Biological E; Christian Medical College; Indian Academy of Paediatrics; Indian Council of Medical Research (ICMR); Indira Gandhi Institute of Child Health; Kempegowda Institute of Medical Sciences; Malankara Orthodox Syrian Christian Medical College Hospital; Ministry of Health; MOSC Medical College Hospital; National Institute of Cholera & Enteric Diseases (NICED); National Rotavirus Reference Laboratory (Vellore); National Rural Health Mission of India, Kochi; Panacea Biotec; Regional Medical Research Center (Bhubaneswar, Orissa); Shantha Biotechnics; Society for Applied Studies; Vani Vilas Hospital Indonesia : BioFarma; Centers for Disease Control & Environmental Health, Ministry of Health; RS Dr. Soetomo Hospital, Surabaya; RS Hasan Sadirin Hospital, Bandung; National Institute of Health Research & Development; Provincial Center for Disease Control, Bali; Sanglah Hospital, Bali; Udayana University
Nepal : Ministry of Health; Patan Hospital (Kathmandu) Niger : Maradi Regional Health Department; Ministry of Health; Tillaberi Regional Health Department Nicaragua : Ministry of Health Pakistan : Aga Khan University; Amson Pharmaceuticals; Karachi City District Government; Ministry of Education, Sindh Province; Ministry of Health; Ministry of Health, Sindh Province Panama : PAHO Regional Office Peoples Republic of China : Changchun Institute of Genetic Engineering Pharmaceuticals; Chinese Centers for Disease Control; Dr. Du Yuping; Fudan University; Guangxi Center for Disease Control and Prevention; Hechi City Centers for Disease Control and Prevention; Jiangsu Provincial Anti-Epidemic Center; Lanzhou Institute of Biological Products; Sinovac Biotech; Wuhan Institute of Biological Products; Xiamen University Philippines : Cebu Institute of Medicine; Philippine Childrens Medical Center; Philippine General Hospital; Philippine Health Insurance Corporation; Research Institute for Tropical Medicine Republic of Korea : Ansan Hospital, Korea University; Asan Medical Center; Chonbuk National University School of Medicine; Celltrion; Chonnam National University; CJ Corporation; Edelman Korea; Green Cross Vaccines; Institut Pasteur Korea; Jeju City hospitals (Halla, HanKook, Hanmeun, Jeju JungAng); Jeju National University Hospital; Jeju Public Health Center; Korea Advanced Institute of Science and Technology (KAIST); Korea Bio-MAX Institute, Seoul National University; Korea Biotechnology Commercialization Center (KBCC); Korea International Cooperation Agency (KOICA); Korea Science and Engineering Foundation; Korea Center for Disease Control; Korea Foundation for International Cooperation of Science and Technology; Korea Institute of Tuberculosis; Korea National Institutes of Health; Korea Research Institute of Bioscience and Biotechnology (KRIBB); Kyungpook National University; LG Sciences; Mogam Institute; National Health Insurance Research Institute, National Health Insurance Corporation; National Research Foundation of Korea; Pohang University of Science and Technology (POSTECH); Seoul National University; Standard Diagnostics; Sungkyunkwan University; Yonsei University Singapore : K.K. Womens and Childrens Hospital; Novartis Institute for Tropical Diseases; Pharm-Olam International; Quintilex East Asia Ptd. Ltd. Sri Lanka : Epidemiology Unit, Ministry of Health; Institut Pasteur Sri Lanka; Lady Ridgeway Hospital; Sengee Gantuya Sweden: Crucell/SBL; Mabtech; University of Gothenburg Switzerland : Crucell/Berna Biotech; Institute for Research in Biomedicine; Medecins sans Frontieres; Novartis; Swiss Tropical and Public Health Institute; Anna Wang Taiwan : National Health Research Institute
14 / 15
Madam Lee Hee-ho, former First Lady of the Republic of Korea who served as the first Honorary President of the KSC for IVI, poses with IVI Board members, KSC members and IVI staff at the presidential office in August 1999.
Australia : Inverness Medical; Murdoch Childrens Research Institute; Panbio; Queensland Institute of Medical Research Bangladesh : Bangladesh Institute of Child Health; Children Health Research Foundation; Dhaka Shishu Hospital; Dhaka Shishu Shasthya Foundation Hospital; ICDDR,B; Kumudini Womens Hospital, Mirzapur Belgium : GlaxoSmithKline (GSK)
Japan : Immunology Frontier Research Center (IFReC), Osaka University; Institute of Tropical Medicine, Nagasaki University; Life Sciences Division, Pentax New Ceramics Division of Hoya Corporation; Tokyo University; University of Ryukyus Kazakhstan : EZ Solution Agency Kenya : Kenya Medical Research Institute (KEMRI) Kyrgyzstan : Ministry of Health
Madam Kwon Yang-suk, former First Lady of the Republic of Korea who served as the second Honorary President of the KSC for the IVI, greets IVI Director-General Dr. John Clemens, at the presidential office.
Brazil : BioManguinhos; Butantan Institute; Ministry of Health Cambodia : Epidemiology Unit, Institut Pasteur; Communicable Disease Control, Ministry of Health; National Dengue Control Program, Ministry of Health; National Pediatric Hospital; US Naval Medical Research Unit 2 Canada : University of Saskatchewan; University of Western Ontario Colombia : Instituto Colombiano de Medicina Tropical CES; Ministry of Health
Madam Kim Yoon-ok, First Lady of the Republic of Korea, currently serves as the Honorary President of the KSC.
Lao PDR : Mahosot Hospital; National Institute of Public Health, Ministry of Health Malaysia : Hospital University Sains Malaysia (HUSM); Hospital Raja Perempuan Zainab II (HRPZII); Universiti Sains Malaysia, Kelantan; Usains Tech Services SDN Mongolia : Maternal and Child Health Hospital; Ministry of Health; Sukhbaatar District Hospital Mozambique : CHAEMS, Ministry of Health, Ministry of Science and Technology Myanmar: Department of Medical Research
Tanzania : Health Sector Programme Support of Danish International Development Agency (DANIDA); National Institute of Medical Research; Public Health LaboratoryIvo de Carneri; Hospital Teule (Muheza); Zanzibar Malaria Research Unit of the Karolinska Institute (ZAMRUKI); Zanzibar Ministry of Health & Social Welfare Thailand : Armed Forces Research Institute of Medical Science (AFRIMS); Center for Disease Control, Ministry of Public Health; Center for Vaccine Development, Mahidol University; Faculty of Public Health, Mahidol University; Kamphaeng Phet-AFRIMS Virology Research Unit (KAVRU); Siriraj Hospital, Mahidol University United Kingdom : Emergent Biosolutions, Inc; Health Protection Agency; London School of Hygiene & Tropical Medicine; National Institute of Biological Standards & Control; Oxford University; Robert Gordon University; Wellcome Trust Sanger Institute United States : Applied Strategies; Arizona State University; Bio-Rad; Biodevelopments - International Institute; Brandeis University; Celldex Therapeutics; Colorado State University; Emmes Co., Ltd.; Family Health International; Focus Diagnostics; Food & Drug Administration; Global Solutions for Infectious Diseases; Harvard University; Hawaii Biotech, Inc.; Henry Jackson Foundation for the Advancement of Military Medicine; InViragen LLC; Institute for Genomic Research; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Los Alamos Joint Genome Research Institute; Massachusetts Institute of Technology (MIT); Merck & Co; National Institute of Child Health and Development, National Institutes of Health (NIH); National Institute of Allergy & Infectious Diseases (NIAID), NIH; Pfizer, Inc.; Program for Appropriate Technology in Health (PATH); Project Resource Group; Purdue University; Quest Diagnostics; Quintiles; Scripps Research Institute; University of California, Berkeley; University of
Hawaii; University of Maryland; University of Michigan; University of North Carolina, Chapel Hill; University of Rochester Medical Center; University of Texas Medical Branch at Galveston; University of Wisconsin; US Centers for Disease Control & Prevention; Walter Reed Army Institute of Research (WRAIR); Washington University; Wayne State University; Roy Widdus Venezuela : Epidemiological Surveillance Headquarters, Ministry of Health & Social Welfare Vietnam : Hai Phong Childrens Hospital; Hanoi Tuberculosis Hospital; Ha Tay Health Services; Khanh Hoa General Hospital; Khanh Hoa Health Services; Ha Tay Provincial Preventive Medicine Center; Institut Pasteur Nha Trang; Institute for Vaccines & Other Biological Substances (IVAC); Institut Pasteur Ho Chi Minh City; Khanh Hoa Tuberculosis Hospital; National Institute of Hygiene & Epidemiology (NIHE); Oxford University Clinical Research Unit; VaBiotech; Vinh Phuc Provincial Hospital; Vinh Phuc Provincial Preventive Medicine Center International : Asia-Pacific International Molecular Biology Network (A-IMBN); Developing Countries Vaccine Manufacturers Network (DCVMN); GAVI Alliance; PanAmerican Health Organization (PAHO); UNICEF-UNDPWorld Bank-WHO Special Programme for Research & Training in Tropical Diseases (TDR); World Health Organization (WHO); WHO Developing Countries Vaccine Regulators Network; WHO Initiative for Vaccine Research (IVR); WHO Regional Office for Europe (EURO); WHO Regional Office for South-East Asia (SEARO); WHO Regional Office for the Western Pacific (WPRO)
BOARD OF TRUSTEES
Prof. Ragnar Norrby Chairman Director General Swedish Institute for Infectious Disease Control Stockholm, Sweden Ms. Ji-ah Paik Director-General International Organizations Ministry of Foreign Affairs and Trade, Republic of Korea Dr. John D. Clemens Director-General International Vaccine Institute Seoul, Republic of Korea Dr. Young-soo Shin Regional Director WHO Western Pacific Regional Office(WPRO) Manila, Philippines Mr. Kidong Song Director-General International Cooperation Bureau Ministry of Education, Science, and Technology, Republic of Korea Mr. George Bickerstaff Member, GAVI Alliances board Managing Director of CRT Capital Group, LLC, CT, USA Dr. Margaret Ann Liu ProTherimmune CA, USA Visiting professor Karolinska Institute Stockholm, Sweden To be appointed The GAVI Alliance Geneva, Switzerland Romulo Garcia Director, Northeast Asia and Mekong Division, Regional Bureau for Asia and the Pacific, UNDP, New York, USA
Dr. Margaret Chan (or her nominee) Director-General World Health Organization Avenue, Geneva, Switzerland Mr. Vijay B. Samant President and CEO Vical, Incorporated, San Diego, CA, USA Dr. Roger Glass Director, Fogarty International Center Associate Director for International Research, National Institutes of Health, Bethesda, MD, USA Dr. Francisco Songane Former Director Partnership for Maternal Newborn and Child Health (PMNCH) Geneva, Switzerland Dr. Nguyen Tran Hien Director, National Institute of Hygiene and Epidemiology Faculty of Public Health, Hanoi Medical University Hanoi, Vietnam Dr. Juhani Eskola National Institute for Health and Welfare (THL), Finland Prof. Peter Martins Ndumbe Dean, Faculty of Health Sciences University of Buea Molyko-BueaSouth West Region, Cameroon Prof. Adel A.F. Mahmoud Department of Molecular Biology and the Woodrow Wilson School of Public and International Affairs, Princeton University, Princeton, NJ, USA
Prof. Barry R. Bloom - Chairman Emeritus Former Dean, Harvard School of Public Health Boston, Massachusetts, USA
REPRESENTING MEMBER COUNTRIES Dr. Vishwa Mohan Katoch Director-General of Indian Council of Medical Research (ICMR) Secretary to Government of India, Department of Health Research New Delhi, India Prof. Claire J. P. Boog Scientific Director Netherlands Vaccine Institute AL Bilthoven, The Netherlands Dr. Carlos Segovia Deputy Director, International Research Programs and Institutional Relations Instituto de Salud Carlos III Ministry of Health and Consumption Madrid, Spain Dr. Ann-Mari Larsdotter Svennerholm Professor Department of Microbiology and Immunology Goteborg University Sweden Dr. Akira Homma Director, Institute of Technology for Immunologicals Bio-Manguinhos of the Oswaldo Cruz Foundation (Fiocruz) Rio de Janeiro, Brazil
16 / 17
Prof. Robert E. Black (Chairman) Professor, International Health Bloomberg School of Public Health Johns Hopkins University Baltimore, Maryland, U.S.A. Dr. Costante Ceccarini S.C. Catignano Siena, Italy Prof. Ian David Gust Emeritus Professor Department of Microbiology and Immunology University of Melbourne Parkville, Victoria Australia Prof. Jan Holmgren Professor Gothenburg University Vaccine Research Institute and Department of Microbiology and Immunology Gothenburg University Gothenburg, Sweden Dr. Marie-Paule Kieny Director Initiative for Vaccine Research (IVR) World Health Organization (WHO) Geneva, Switzerland Prof. Byoung S. Kwon Endowed Investigator Division of Cell and Immunobiology R&D Center for Cancer Therapeutics National Cancer Center Ilsan District, Goyang, Gyeonggi Province, Republic of Korea
Prof. Ira M. Longini Department of Biostatistics School of Public Health and Community Medicine University of Washington Seattle, Washington, U.S.A. Prof. Jacques Louis Professor Emeritus Faculty of Medicine, University of Lausanne, Switzerland Director Emeritus, Department of Parasitology and Mycology, Institut Pasteur, Paris, France Prof. Moon H. Nahm Professor, Departments of Pathology and Microbiology Director of the Clinical Immunology Laboratory University of Alabama at Birmingham Birmingham, Alabama, U.S.A. Dr. G. Balakrish Nair Director National Institute of Cholera and Enteric Diseases (NICED) Kolkata, India Prof. Pearay L. Ogra John Sealy Distinguished Chair Professor and Chairman (Emeritus) Department of Pediatrics University of Texas Medical Branch: Professor of Pediatrics State University of New York at Buffalo Childrens Hospital Buffalo, New York, U.S.A.
Prof. Peter Smith Department of Epidemiology and Population Health London School of Hygiene and Tropical Medicine London, U.K. Dr. Yoshifumi Takeda Director Collaborative Research Center of Okayama University for Infectious Diseases in India, National Institute of Cholera and Enteric Diseases (NICED) Kolkata, India
FACILITIES COMMITTEE Prof. Gordon Dougan Principal Research Scientist Member of the Board of Management The Wellcome Trust Sanger Institute Cambridge, U.K. Prof. Margaret A. Liu ProTherImmune Visiting Professor of Karolinska Institute, Stockholm, Sweden Lafayette, California, U.S.A.
Bangladesh
Bhutan
Brazil
China
Cote dlvoire
Ecuador
Egypt
India
Indonesia
Israel
Jamaica
Kazakhstan
Kuwait
Kyrgyzstan
Lebanon
Liberia
Malta
Mongolia
Myanmar
Nepal
Netherlands
Oman
Pakistan
Panama
18 / 19
Peru
Philippines
Republic of Korea
Romania
Senegal
Slovak Republic
Spain
Sri Lanka
Sweden
Tajikistan
Thailand
Turkey
Uzbekistan
Vietnam